Akebia Therapeutics reported that a post‑hoc win statistics analysis of its global Phase 3 INNO2VATE program has been published in the Journal of the American Society of Nephrology. The analysis compared Vafseo (vadadustat) with darbepoetin alfa in adults with anemia due to chronic kidney disease who have been on dialysis for at least three months.
The study, which included all randomized patients who received at least one dose of study drug, found a statistically significant improvement in a composite endpoint of all‑cause mortality and hospitalization. Vafseo patients experienced lower rates of the composite endpoint compared with darbepoetin alfa, supporting Vafseo’s positioning as a potential standard of care in the dialysis market.
Vafseo, an oral hypoxia‑inducible factor prolyl hydroxylase inhibitor, was approved by the FDA in March 2024 and became available in the U.S. in January 2025. The publication of the analysis in a peer‑reviewed journal provides robust evidence that may influence prescriber adoption and reimbursement discussions.
The analysis employed a win statistics approach, a method that prioritizes the most clinically relevant events, but the specific statistical parameters were not disclosed in the article. Dr. Steven Burke, Chief R&D and Medical Officer, said the win statistics analysis “highlights favorable outcomes and potential clinical differentiation for Vafseo that we believe are central to ensuring informed clinical decision‑making for nephrologists and other care providers.” CEO John P. Butler added that the study “further validates the strength of the vadadustat dataset and supports strong engagement with prescribers, providers and payors.”
The study’s findings come at a time when Akebia’s commercial performance has accelerated. In Q1 2025, Vafseo generated $12.0 million in net product revenues, and the company’s total revenues rose to $57.3 million, up from $32.6 million in Q1 2024. The company’s net income of $6.1 million in Q1 2025 marked a turnaround from a $18.0 million loss in Q1 2024, underscoring the commercial momentum behind Vafseo.
While the article does not provide specific hazard ratios or percentage reductions, the statistically significant improvement in the composite endpoint indicates a clinically meaningful benefit that could strengthen Vafseo’s market position and support future reimbursement negotiations.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.